NCT03667417Recruiting
Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
Cohort of subjects carrying a BRCA gene mutation: genetic predispositions to breast and ovarian cancers
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 5000 (estimated)
- First submitted
- 10 Sept 2018
- Start date
- 15 Oct 1999
- Primary completion date
- 15 Oct 2028
- Lead sponsor
- Institut Paoli-Calmettes
- Diseases
- Ovarian cancer
- NCT number
- NCT03667417
What you commit to
- Study type: Observational
- Planned participants: 5000
- From 15 Oct 1999 to the primary completion date, 15 Oct 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- A person of legal age subject to a legal protection measure, or unable to express consent.
Other
- Impossibility to submit to the follow-up of the test for geographical, social or psychological reasons
Criteria the registry did not label
- Woman or man, with or without cancer, carrying a deleterious BRCA1/BRCA2 mutation, aged 18 years and over.
- Woman with or without breast cancer or ovarian cancer at baseline.
- Man with or without breast cancer at baseline.
- Signed consent to participation
- Affiliation to a social security regimen, or beneficiary of such a regimen.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Paoli-Calmettes Coordinator of this site? Confirm its status | Marseille | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.